New hope for rare blood disorder: ruxolitinib trial targets eosinophils
NCT ID NCT03801434
First seen Jan 06, 2026 · Last updated Apr 29, 2026 · Updated 22 times
Summary
This study tests the drug ruxolitinib in 10 people with hypereosinophilic syndrome or related disorders, where high levels of eosinophils (a type of white blood cell) cause organ damage. The goal is to see if ruxolitinib can lower eosinophil counts and improve symptoms. Participants must have tried other treatments without success or be unable to take them.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPEREOSINOPHILIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutchinson cancer research center
TERMINATEDSeattle, Washington, 98109, United States
-
OHSU Knight Cancer Institute
TERMINATEDPortland, Oregon, 97201, United States
-
Stanford Cancer Institute Palo Alto
RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Utah
TERMINATEDSalt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.